Internationally Leading Research Strength

Darwin brings together many international cell biology scientists as a scientific research team, and has an independent GMP cell biology laboratory certified by the National Double Standard.

Darwin Center Laboratory

Darwin Independent Biological Laboratory is one of the first laboratories to be awarded the national dual standard certification under the new GMP laboratory validation standard adopted by the State, which can meet the needs of innovative development experimental research for medical translation of biomedical technology and the cultivation of cells for production research under GMP conditions.

Darwin Clinical Laboratory

It can satisfy the experimental research of innovative development of medical transformation of biomedical technology, and can cultivate and produce cells for research under GMP conditions, and is a platform laboratory for biotechnology in the whole field of genes, cells, proteins and PCR.

Darwin Norco Plant

Darwin Nogol (Beijing) Biotechnology Co., Ltd. is the first biomaterials production base of Darwin Cell Biology Group, which is a "bio-wise factory" integrating independent R&D capability, scientific and technological innovation capability, industrial transformation capability, and product market transformation capability. In accordance with the requirements of Good Manufacturing Practice (GMP), it is equipped with first-class equipment and leading manufacturing processes, and specializes in the production of biomaterials. In the first phase, the plant will meet the production needs of its subsidiaries for three types of medical devices, including nerve sheaths, nerve patches and orthopedic consumables.

The company has three R&D centers, two pilot platforms and one clinical center; 33 R&D elites, 23 senior researchers and 50 clinical research experts. At present, the company has four major technology platforms: stem cell stress induction technology platform, functional protein discovery and screening technology platform, neurological disease drug efficacy screening platform and IIT clinical trial platform. There are 3 core drug pipelines and 7 reserve pipelines; among them, 90% is an innovative biopharmaceutical, 80% is targeted at the treatment of neurological diseases, and 50% meets the criteria for breakthrough therapies.